HRP20050432A2 - Novel medicaments for the treatment of chronic obstructive pulmonary diseases - Google Patents

Novel medicaments for the treatment of chronic obstructive pulmonary diseases

Info

Publication number
HRP20050432A2
HRP20050432A2 HR20050432A HRP20050432A HRP20050432A2 HR P20050432 A2 HRP20050432 A2 HR P20050432A2 HR 20050432 A HR20050432 A HR 20050432A HR P20050432 A HRP20050432 A HR P20050432A HR P20050432 A2 HRP20050432 A2 HR P20050432A2
Authority
HR
Croatia
Prior art keywords
treatment
chronic obstructive
obstructive pulmonary
pulmonary diseases
novel medicaments
Prior art date
Application number
HR20050432A
Other languages
Croatian (hr)
Inventor
Hoenke Christoph
Lustenberger Philipp
Rudolf Klaus
Bouyssou Thierry
Buettner Frank
Konetzki Ingo
Pestel Sabine
Schnapp Andreas
Schollenberger Hermann
Schromm Kurt
Heine Claudia
Original Assignee
Boehringer Ingelheim Pharma Gmbh & Co.Kg.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32185709&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20050432(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Pharma Gmbh & Co.Kg. filed Critical Boehringer Ingelheim Pharma Gmbh & Co.Kg.
Publication of HRP20050432A2 publication Critical patent/HRP20050432A2/en
Publication of HRP20050432B1 publication Critical patent/HRP20050432B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring

Abstract

Predloženi izum odnosi se na upotrebu spojeva opće formule 1,u kojoj radikali R1, R2 i R3 mogu imati značenja navedena u patentnim zahtjevima i u opisu, za proizvodnju lijeka za liječenje COPD-a (kronična opstrukcijska bolest pluća, e. chronic obstructive pulmonarv disease), kao i na nove spojeve opće formule 1 kao takove.The present invention relates to the use of compounds of general formula 1, in which the radicals R1, R2 and R3 may have the meanings given in the claims and in the description, for the manufacture of a medicament for the treatment of COPD (chronic obstructive pulmonary disease). , as well as to novel compounds of general formula 1 as such.

HR20050432A 2002-11-15 2005-05-13 Novel medicaments for the treatment of chronic obstructive pulmonary diseases HRP20050432B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10253282A DE10253282A1 (en) 2002-11-15 2002-11-15 Treatment of chronic obstructive pulmonary disease, using new or known N-substituted 2-amino-1-(benz-(1,4)-oxazin-3-on-8-yl)-ethanol derivative beta-mimetic agents, suitable for once-daily administration
PCT/EP2003/012565 WO2004045618A2 (en) 2002-11-15 2003-11-11 Novel medicaments for the treatment of chronic obstructive pulmonary diseases

Publications (2)

Publication Number Publication Date
HRP20050432A2 true HRP20050432A2 (en) 2006-06-30
HRP20050432B1 HRP20050432B1 (en) 2012-01-31

Family

ID=32185709

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20050432A HRP20050432B1 (en) 2002-11-15 2005-05-13 Novel medicaments for the treatment of chronic obstructive pulmonary diseases

Country Status (38)

Country Link
EP (2) EP1562603B3 (en)
JP (1) JP4317138B2 (en)
KR (1) KR101092247B1 (en)
CN (3) CN101735166A (en)
AR (2) AR041969A1 (en)
AT (1) ATE430569T1 (en)
AU (1) AU2003285326B2 (en)
BE (1) BE2014C016I2 (en)
BR (1) BRPI0316264B8 (en)
CA (1) CA2506082C (en)
CO (1) CO5570670A2 (en)
CY (2) CY1110500T1 (en)
DE (2) DE10253282A1 (en)
DK (1) DK1562603T3 (en)
EA (1) EA008665B1 (en)
EC (1) ECSP055774A (en)
ES (1) ES2326878T7 (en)
FR (1) FR14C0049I2 (en)
HR (1) HRP20050432B1 (en)
HU (1) HUS1400011I1 (en)
IL (1) IL167900A (en)
LT (1) LTC1562603I2 (en)
LU (1) LU92433I2 (en)
ME (1) ME00354B (en)
MX (1) MXPA05005081A (en)
MY (1) MY136034A (en)
NL (1) NL300650I2 (en)
NO (2) NO334314B1 (en)
NZ (1) NZ540661A (en)
PE (1) PE20040694A1 (en)
PL (1) PL212238B1 (en)
PT (1) PT1562603E (en)
RS (1) RS51607B (en)
SI (1) SI1562603T1 (en)
TW (1) TWI343812B (en)
UA (1) UA81276C2 (en)
WO (1) WO2004045618A2 (en)
ZA (1) ZA200502246B (en)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7056916B2 (en) 2002-11-15 2006-06-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments for the treatment of chronic obstructive pulmonary disease
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
DE102004019539A1 (en) * 2004-04-22 2005-11-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg New drugs for the treatment of respiratory diseases
SG152237A1 (en) * 2004-04-22 2009-05-29 Boehringer Ingelheim Int Pharmaceutical combinations containing benzoxazine for treating respiratory diseases
WO2005110990A1 (en) * 2004-05-13 2005-11-24 Boehringer Ingelheim International Gmbh Hydroxy-substituted benzo-condensed heterocycles for use as beta agonists in the treatment of respiratory diseases
US20050256115A1 (en) * 2004-05-14 2005-11-17 Boehringer Ingelheim International Gmbh Aerosol formulation for the inhalation of beta-agonists
DE102004024452A1 (en) * 2004-05-14 2005-12-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Aerosol formulation for the inhalation of beta agonists
DE102004024454A1 (en) * 2004-05-14 2005-12-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Novel enantiomerically pure beta agonists, process for their preparation and their use as pharmaceuticals
DE102004024451A1 (en) * 2004-05-14 2005-12-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Powder formulations for inhalation containing enantiomerically pure beta agonists
US7220742B2 (en) 2004-05-14 2007-05-22 Boehringer Ingelheim International Gmbh Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
US7745621B2 (en) 2004-05-14 2010-06-29 Boehringer Ingelheim International Gmbh Long acting bronchodilators for the treatment of respiratory diseases
DE102004024453A1 (en) * 2004-05-14 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg New long-acting bronchodilators for the treatment of respiratory diseases
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
DE102004045648A1 (en) * 2004-09-21 2006-03-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg New betamimetics for the treatment of respiratory diseases
GT200500281A (en) 2004-10-22 2006-04-24 Novartis Ag ORGANIC COMPOUNDS.
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
DE102005007654A1 (en) 2005-02-19 2006-08-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg New long-acting betamimetics for the treatment of respiratory diseases
GB0507577D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
DE102005030733A1 (en) * 2005-07-01 2007-01-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg New drug combinations for the treatment of respiratory diseases containing long-acting beta-2 agonists and at least one other active ingredient
GB0516313D0 (en) 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses
NZ566068A (en) 2005-08-08 2011-03-31 Argenta Discovery Ltd Bicyclo[2.2.1]hept-7-ylamine derivatives and their uses
JP5270343B2 (en) 2005-08-15 2013-08-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Beta mimetic manufacturing method
US20070088030A1 (en) 2005-10-10 2007-04-19 Barbara Niklaus-Humke Aerosol formulations for the inhalation of beta-agonists
TWI396541B (en) 2005-10-10 2013-05-21 Boehringer Ingelheim Int Novel combinations of medicaments for the treatment of respiratory diseases
EP2532678A1 (en) 2005-10-21 2012-12-12 Novartis AG Human antibodies against il13 and therapeutic uses
BRPI0618370A2 (en) * 2005-11-09 2011-08-30 Boehringer Ingelheim Int aerosol drug formulation, drug use and inhalation kit
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
WO2007093608A1 (en) * 2006-02-16 2007-08-23 Boehringer Ingelheim International Gmbh Drug combinations for the treatment of respiratory tract diseases
PE20080142A1 (en) * 2006-03-15 2008-04-14 Boehringer Ingelheim Int ENANTHOMERICALLY PURE BETA-AGONISTS AND THEIR PREPARATION PROCEDURES
PT2013211E (en) 2006-04-21 2012-06-21 Novartis Ag Purine derivatives for use as adenosin a2a receptor agonists
WO2008017638A1 (en) * 2006-08-07 2008-02-14 Boehringer Ingelheim International Gmbh Single enantiomer beta-agonists, methods for the production thereof and the use thereof as medication
UY30542A1 (en) * 2006-08-18 2008-03-31 Boehringer Ingelheim Int AEROSOL FORMULATION FOR INHALATION OF BETA AGONISTS
UY30543A1 (en) * 2006-08-18 2008-03-31 Boehringer Ingelheim Int AEROSOL FORMULATION FOR INHALATION OF BETA- AGONISTS
ATE502943T1 (en) 2006-09-29 2011-04-15 Novartis Ag PYRAZOLOPYRIMIDINES AS PI3K LIPID KINASE INHIBITORS
CN101522682A (en) 2006-10-30 2009-09-02 诺瓦提斯公司 Heterocyclic compounds as antiinflammatory agents
WO2008085608A1 (en) 2007-01-10 2008-07-17 Irm Llc Compounds and compositions as channel activating protease inhibitors
US20100022770A1 (en) * 2007-01-25 2010-01-28 Boehringer Ingelheim International Gmbh Process for the manufacturing of beta mimetics
PL2155721T3 (en) 2007-05-07 2011-07-29 Novartis Ag Organic compounds
CL2008003651A1 (en) 2007-12-10 2009-06-19 Novartis Ag Substituted 3,5-diamino-6-chloropyrazinamide derivative compounds; pharmaceutical composition; pharmaceutical combination; and use in the treatment of an inflammatory or allergic condition, in particular an inflammatory or obstructive disease of the airways.
PL2231642T3 (en) 2008-01-11 2014-04-30 Novartis Ag Pyrimidines as kinase inhibitors
BRPI0915018A2 (en) 2008-06-10 2015-10-27 Novartis Ag organic compounds
US8236786B2 (en) 2008-08-07 2012-08-07 Pulmagen Therapeutics (Inflammation) Limited Respiratory disease treatment
US8362064B2 (en) 2008-12-30 2013-01-29 Pulmagen Theraputics (Inflammation) Limited Sulfonamide compounds for the treatment of respiratory disorders
US20110281917A1 (en) 2009-01-29 2011-11-17 Darrin Stuart Substituted Benzimidazoles for the Treatment of Astrocytomas
WO2010150014A1 (en) 2009-06-24 2010-12-29 Pulmagen Therapeutics (Inflammation) Limited 5r- 5 -deuterated glitazones for respiratory disease treatment
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
EA201200260A1 (en) 2009-08-12 2012-09-28 Новартис Аг HETEROCYCLIC HYDRAZONES AND THEIR APPLICATION FOR THE TREATMENT OF CANCER AND INFLAMMATION
MX2012002066A (en) 2009-08-17 2012-03-29 Intellikine Inc Heterocyclic compounds and uses thereof.
AU2010310449A1 (en) 2009-10-22 2012-05-03 Vertex Pharmaceuticals Incorporated Compositions for treatment of cystic fibrosis and other chronic diseases
GB0918924D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Azaindole derivatives
GB0918923D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminothiazole derivatives
GB0918922D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminopyridine derivatives
WO2011098746A1 (en) 2010-02-09 2011-08-18 Pulmagen Therapeutics (Inflammation) Limited Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone
GB201002224D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
GB201002243D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
EA024925B1 (en) * 2010-09-21 2016-11-30 Интекрин Терапьютикс, Инк. Antidiabetic solid pharmaceutical compositions
WO2012107500A1 (en) 2011-02-10 2012-08-16 Novartis Ag [1, 2, 4] triazolo [4, 3 -b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
US9127000B2 (en) 2011-02-23 2015-09-08 Intellikine, LLC. Heterocyclic compounds and uses thereof
CA2828219A1 (en) 2011-02-25 2012-08-30 Irm Llc Pyrazolo [1,5-a] pyridines as trk inhibitors
UY34305A (en) 2011-09-01 2013-04-30 Novartis Ag DERIVATIVES OF BICYCLIC HETEROCICLES FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION
MX339302B (en) 2011-09-15 2016-05-19 Novartis Ag 6 - substituted 3 - (quinolin- 6 - ylthio) - [1,2,4] triazolo [4, 3 -a] pyradines as tyrosine kinase.
WO2013038381A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
WO2013038378A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013038386A1 (en) 2011-09-16 2013-03-21 Novartis Ag Heterocyclic compounds for the treatment of cystic fibrosis
WO2013038373A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013038390A1 (en) 2011-09-16 2013-03-21 Novartis Ag N-substituted heterocyclyl carboxamides
WO2013078440A2 (en) 2011-11-23 2013-05-30 Intellikine, Llc Enhanced treatment regimens using mtor inhibitors
US8809340B2 (en) 2012-03-19 2014-08-19 Novartis Ag Crystalline form
WO2013149581A1 (en) 2012-04-03 2013-10-10 Novartis Ag Combination products with tyrosine kinase inhibitors and their use
JP2015533131A (en) * 2012-10-09 2015-11-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Beta2-adrenergic receptor agonists for treating cough
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
WO2014151147A1 (en) 2013-03-15 2014-09-25 Intellikine, Llc Combination of kinase inhibitors and uses thereof
WO2015084804A1 (en) 2013-12-03 2015-06-11 Novartis Ag Combination of mdm2 inhibitor and braf inhibitor and their use
CA2945257A1 (en) 2014-04-24 2015-10-29 Novartis Ag Pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
BR112016024484A2 (en) 2014-04-24 2017-08-15 Novartis Ag aminopyridine derivatives as phosphatidylinositol 3-kinase inhibitors
EA032075B1 (en) 2014-04-24 2019-04-30 Новартис Аг Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
RU2695230C2 (en) 2014-07-31 2019-07-22 Новартис Аг Combined therapy
WO2018108669A1 (en) 2016-12-12 2018-06-21 Boehringer Ingelheim International Gmbh Nintedanib for use in methods for the treatment of interstitial lung diseases by coadministration with olodaterol
DK3558954T3 (en) 2016-12-20 2021-12-06 Inke Sa IMPROVED PROCESS FOR PREPARATION OF R-6-HYDROXY-8- [1-HYDROXY-2- [2- (4METHOXYPHENYL) -1,1-DIMETHYLETHYLAMINOETHYL] -2H-1,4-BENZOXAZIN-3DYHONE-4DROCHONE-4DROCHO
CN108997248B (en) * 2018-08-06 2023-08-01 上海方予健康医药科技有限公司 Crystal form B of ondarot hydrochloride and preparation method thereof
CN109096218B (en) * 2018-08-06 2020-10-27 上海方予健康医药科技有限公司 Oxydterol hydrochloride crystal form A and preparation method thereof
CN113891744A (en) 2019-06-10 2022-01-04 诺华股份有限公司 Pyridine and pyrazine derivatives for the treatment of CF, COPD and bronchiectasis
EP4021572A1 (en) 2019-08-28 2022-07-06 Novartis AG Substituted 1,3-phenyl heteroaryl derivatives and their use in the treatment of disease
US11304897B2 (en) 2020-06-09 2022-04-19 Anovent Pharmaceutical (U.S.), Llc Pharmaceutical formulation containing umeclidinium bromide and vilanterol trifenatate
US11331322B1 (en) 2021-09-15 2022-05-17 Santen Pharmaceutical Co., Ltd. Medicament for preventing and/or treating dry eye

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3134590A1 (en) * 1981-09-01 1983-03-10 Boehringer Ingelheim KG, 6507 Ingelheim NEW BENZO HETEROCYCLES
US4460581A (en) 1982-10-12 1984-07-17 Boehringer Ingelheim Kg (1-Hydroxy-2-amino-alkyl)-substituted benzoxazinones and benzoxazolinones
DE3743265A1 (en) * 1987-12-19 1989-06-29 Boehringer Ingelheim Kg NEW AMMONIUM COMPOUNDS, THEIR MANUFACTURE AND USE
BR0110331A (en) * 2000-04-27 2003-01-07 Boehringer Ingelheim Pharma Beta-mimicking substances that have long-lasting activity, processes for preparing them and their use as medicines

Also Published As

Publication number Publication date
LU92433I2 (en) 2014-06-24
NL300650I2 (en) 2017-11-02
IL167900A (en) 2013-06-27
WO2004045618A3 (en) 2004-09-30
CN1713914A (en) 2005-12-28
KR101092247B1 (en) 2011-12-12
FR14C0049I2 (en) 2015-07-24
RS20050361A (en) 2007-04-10
EP1562603A2 (en) 2005-08-17
ES2326878T3 (en) 2009-10-21
NO334314B1 (en) 2014-02-03
PE20040694A1 (en) 2004-11-23
ZA200502246B (en) 2006-01-25
JP4317138B2 (en) 2009-08-19
PT1562603E (en) 2009-06-18
CN101735166A (en) 2010-06-16
HUS1400011I1 (en) 2022-02-28
TWI343812B (en) 2011-06-21
DE50311502D1 (en) 2009-06-18
PL375270A1 (en) 2005-11-28
CN101817800A (en) 2010-09-01
CY1110500T1 (en) 2015-04-29
BRPI0316264B8 (en) 2021-05-25
ME00354B (en) 2011-10-10
BR0316264A (en) 2005-10-11
AR087241A2 (en) 2014-03-12
NZ540661A (en) 2007-12-21
EP2025338A1 (en) 2009-02-18
RS51607B (en) 2011-08-31
EP1562603B3 (en) 2014-01-08
CA2506082A1 (en) 2004-06-03
BE2014C016I2 (en) 2023-03-07
CY2014032I2 (en) 2015-12-09
UA81276C2 (en) 2007-12-25
JP2006508140A (en) 2006-03-09
ATE430569T1 (en) 2009-05-15
AU2003285326B2 (en) 2009-06-04
PL212238B1 (en) 2012-08-31
MXPA05005081A (en) 2005-07-01
DE10253282A1 (en) 2004-05-27
KR20050075013A (en) 2005-07-19
AU2003285326A1 (en) 2004-06-15
AR041969A1 (en) 2005-06-01
MEP53608A (en) 2011-05-10
DK1562603T3 (en) 2009-09-07
CA2506082C (en) 2011-06-21
ECSP055774A (en) 2005-11-22
EA008665B1 (en) 2007-06-29
ES2326878T7 (en) 2014-03-11
NO2014005I1 (en) 2014-03-10
NO20052883L (en) 2005-06-14
CY2014032I1 (en) 2015-12-09
TW200423943A (en) 2004-11-16
MY136034A (en) 2008-07-31
LTC1562603I2 (en) 2016-12-12
SI1562603T1 (en) 2009-10-31
WO2004045618A2 (en) 2004-06-03
FR14C0049I1 (en) 2014-08-08
EP1562603B1 (en) 2009-05-06
EA200500715A1 (en) 2005-12-29
CO5570670A2 (en) 2005-10-31
BRPI0316264B1 (en) 2019-04-09
HRP20050432B1 (en) 2012-01-31

Similar Documents

Publication Publication Date Title
HRP20050432A2 (en) Novel medicaments for the treatment of chronic obstructive pulmonary diseases
SE0102300D0 (en) Compounds
ME00376B (en) Dihydropteridinones, method for the production and use thereof in the form of drugs
NO20065061L (en) Benzoxazine for the treatment of respiratory diseases
NO20063275L (en) Use of substituted 2-aminotetralins for the prophylaxis of Parkinson's disease
NO20062983L (en) Sulfonamide derivatives for the treatment of diseases
MEP13408A (en) Cdk inhibiting pyrimidines, production thereof and their use as medicaments
DK1689721T3 (en) Aminopyrazole derivatives as GSK-3 inhibitors
DE60220887D1 (en) AGONISTS OF BETA ADRENORE RECEPTORS
EA200401114A2 (en) SUBSTITUTED HYDROXYETHYLAMINES
DE60215814D1 (en) Vinylphenyl derivatives as Glk activators
TW200604196A (en) New quinuclidine derivatives and pharmaceutical compositions comprising them
NO20063761L (en) Sulfonamide derivatives for the treatment of diseases
CY1106857T1 (en) 4-(AMINOMETHYL)-PIPERIDINE BENZAMIDES AS 5HT4-ANTEGONISTS
ATE409480T1 (en) PYRAZOLOA3,4-BUPYRIDINE-6-ONE AS GSK-3 INHIBITORS
BR0306922A (en) N-pyrazinyl phenylsulfonamides and their use in the treatment of chemokine mediated diseases
CY1111256T1 (en) AZADICYCLOKTAN-3-ONE PRODUCTS AND THEIR USE
BRPI0519267A2 (en) quinoline derivative, its use, production and medicine containing the same
HK1079526A1 (en) A novel pyrazine compound and its use in the manufacture of a medicament for treating diseases related to serotonin
MEP42908A (en) Substituted 4-phenyltetrahydroisoquinolines, method for the production thereof, the use of the same as medicaments, and medicament containing such compounds
IL166057A0 (en) Urea-substituted and urethane-substituted acylureas methods for the production thereof and their useas medicaments
EA200600054A1 (en) 4- (AMINOMETHYL) PIPERIDINBENZAMIDES OWNED WITH 5HT-ANTAGONISTIC ACTIVITY
MXPA04003938A (en) Heterocyclic retinoid compounds.
UY28078A1 (en) NEW MEDICINAL PRODUCT FOR THE TREATMENT OF THE CHRONIC OBSTRUCTIVE PULMONARY DISEASE
NO20064805L (en) Compositions for the treatment of diseases

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20181106

Year of fee payment: 16

ODRP Renewal fee for the maintenance of a patent

Payment date: 20191022

Year of fee payment: 17

ODRP Renewal fee for the maintenance of a patent

Payment date: 20201102

Year of fee payment: 18

ODRP Renewal fee for the maintenance of a patent

Payment date: 20211109

Year of fee payment: 19

ODRP Renewal fee for the maintenance of a patent

Payment date: 20221107

Year of fee payment: 20

PB20 Patent expired after termination of 20 years

Effective date: 20231111